Content
75%Weight 40%Scale 1-5Reviews the quality of instructions and guidance provided to agents. Good implementation is clear, handles edge cases, and produces reliable results.
A highly actionable, well-sequenced research workflow with concrete executable tool calls and strong fallback guidance. The main weakness is conciseness — several step openings restate pharmacology basics Claude already knows — and the absence of any progressive-disclosure split for the larger reference-style sections.
Suggestions
Trim the concept-explanation openings of Steps 3-7 ('Most drugs bind more than one target…', 'A drug target does not work in isolation…') to assume Claude's pharmacology knowledge.
Consider moving the full report-structure template and the drug-comparison guidance into a reference file to reduce SKILL.md length and improve progressive disclosure.
Add a brief verification checkpoint in Step 8 (e.g. confirm each report section has at least one sourced finding) to lift workflow clarity toward the top anchor.
| Dimension | Reasoning | Score |
|---|---|---|
Conciseness | The bulk is executable code and useful reasoning strategies, but several steps open with pharmacology concepts Claude already knows ('Most drugs bind more than one target', 'A drug target does not work in isolation', 'Drug labels describe WHAT the drug does'). | 3 / 5 |
Actionability | Copy-paste-ready tu.tools.* calls with real identifiers (CHEMBL1431, metformin, PRKAA1), a fallback strategies table, and a report template fully cover the common investigation cases. | 5 / 5 |
Workflow Clarity | A clear 8-step sequence with fallbacks, 'Known issue' notes, and an evidence hierarchy; read-only research so the destructive/batch cap does not apply, but explicit verification checkpoints are absent. | 4 / 5 |
Progressive Disclosure | Single ~280-line file with well-organized section headers and no bundle files to reference; the report template and comparison guidance are reasonably inline for a cohesive workflow, with only minor organization gaps. | 4 / 5 |
Total | 16 / 20 Passed |